SG11202006712XA - Treatment of ophthalmologic diseases - Google Patents
Treatment of ophthalmologic diseasesInfo
- Publication number
- SG11202006712XA SG11202006712XA SG11202006712XA SG11202006712XA SG11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- ophthalmologic diseases
- ophthalmologic
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627103P | 2018-02-06 | 2018-02-06 | |
| US201862729333P | 2018-09-10 | 2018-09-10 | |
| PCT/EP2019/052704 WO2019154776A1 (en) | 2018-02-06 | 2019-02-05 | Treatment of ophthalmologic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006712XA true SG11202006712XA (en) | 2020-08-28 |
Family
ID=65352014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006712XA SG11202006712XA (en) | 2018-02-06 | 2019-02-05 | Treatment of ophthalmologic diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210139576A1 (https=) |
| EP (1) | EP3749359A1 (https=) |
| JP (5) | JP7005772B2 (https=) |
| KR (3) | KR20250166355A (https=) |
| CN (4) | CN111699004A (https=) |
| AU (3) | AU2019219004B2 (https=) |
| CA (1) | CA3088355A1 (https=) |
| IL (1) | IL276383B2 (https=) |
| MX (1) | MX2020007527A (https=) |
| SG (1) | SG11202006712XA (https=) |
| TW (3) | TWI831764B (https=) |
| WO (1) | WO2019154776A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| AU2019212622B2 (en) | 2018-01-26 | 2024-05-23 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| MY195550A (en) | 2018-10-29 | 2023-01-31 | Hoffmann La Roche | Antibody Formulation |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| TWI785360B (zh) * | 2019-08-06 | 2022-12-01 | 美商建南德克公司 | 眼科疾病之個人化治療 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| BR112022010113A2 (pt) | 2019-11-25 | 2022-09-06 | Univ California | Inibidores de vegf de longa ação para neovascularização intraocular |
| TW202216761A (zh) | 2020-07-16 | 2022-05-01 | 瑞士商諾華公司 | 抗β細胞素抗體、其片段及多特異性結合分子 |
| EP4208201A1 (en) * | 2020-09-04 | 2023-07-12 | F. Hoffmann-La Roche AG | Antibody that binds to vegf-a and ang2 and methods of use |
| WO2022057888A1 (zh) * | 2020-09-17 | 2022-03-24 | 江苏恒瑞医药股份有限公司 | 特异性结合vegf和ang-2的双特异性抗原结合分子 |
| JP2024512701A (ja) * | 2021-03-30 | 2024-03-19 | アブプロ コーポレーション | 抗ａｎｇ２×ｖｅｇｆ多重特異性抗体を用いて脈絡膜新生血管形成を治療するための方法 |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| CN118139628A (zh) * | 2021-08-23 | 2024-06-04 | 阿维麦克思生物制药公司 | 用于转基因表达的组合物和方法 |
| CN117100845A (zh) * | 2022-10-24 | 2023-11-24 | 景泽生物医药(合肥)股份有限公司 | 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| CA2785907A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| KR20190049934A (ko) * | 2011-01-13 | 2019-05-09 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| RS60499B1 (sr) | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modifikovani polipeptidi za bispecifične skelete antitela |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| SG11201408538PA (en) * | 2012-07-13 | 2015-02-27 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| CA2879597C (en) * | 2012-08-21 | 2021-01-12 | Opko Pharmaceuticals, Llc | Ophthalmic liposome formulations for treating posterior segment disease |
| WO2014177459A2 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| KR20150063728A (ko) | 2013-12-02 | 2015-06-10 | 삼성전자주식회사 | 항 VEGF-C/항 Ang2 이중 특이 항체 |
| TWI806150B (zh) * | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| CN114306575A (zh) * | 2014-12-11 | 2022-04-12 | 拜耳医药保健有限责任公司 | 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗 |
| AR103477A1 (es) * | 2015-01-28 | 2017-05-10 | Lilly Co Eli | Compuestos de vegfa / ang2 |
| EP3454903A4 (en) | 2016-05-13 | 2020-08-19 | Askgene Pharma, Inc. | NEW DOUBLE ANTAGONISTS OF ANGIOPOIETIN 2, VEGF |
| EP4549463A3 (en) * | 2016-06-17 | 2025-07-30 | F. Hoffmann-La Roche AG | Purification of multispecific antibodies |
-
2019
- 2019-02-05 SG SG11202006712XA patent/SG11202006712XA/en unknown
- 2019-02-05 JP JP2020536578A patent/JP7005772B2/ja active Active
- 2019-02-05 KR KR1020257038946A patent/KR20250166355A/ko active Pending
- 2019-02-05 KR KR1020207025450A patent/KR20200119274A/ko not_active Ceased
- 2019-02-05 CN CN201980011416.4A patent/CN111699004A/zh not_active Withdrawn
- 2019-02-05 AU AU2019219004A patent/AU2019219004B2/en active Active
- 2019-02-05 CN CN202411925146.7A patent/CN119733046A/zh active Pending
- 2019-02-05 EP EP19703978.7A patent/EP3749359A1/en active Pending
- 2019-02-05 IL IL276383A patent/IL276383B2/en unknown
- 2019-02-05 CA CA3088355A patent/CA3088355A1/en active Pending
- 2019-02-05 KR KR1020247016479A patent/KR20240093772A/ko active Pending
- 2019-02-05 MX MX2020007527A patent/MX2020007527A/es unknown
- 2019-02-05 CN CN202510108289.7A patent/CN119909169A/zh active Pending
- 2019-02-05 CN CN202411926524.3A patent/CN119770646A/zh active Pending
- 2019-02-05 WO PCT/EP2019/052704 patent/WO2019154776A1/en not_active Ceased
- 2019-02-11 TW TW108104518A patent/TWI831764B/zh active
- 2019-02-11 TW TW113103154A patent/TWI885720B/zh active
- 2019-02-11 TW TW114116623A patent/TW202535932A/zh unknown
-
2020
- 2020-08-05 US US16/985,477 patent/US20210139576A1/en not_active Abandoned
-
2022
- 2022-01-05 JP JP2022000341A patent/JP7273204B2/ja active Active
-
2023
- 2023-02-09 US US18/166,996 patent/US20230416353A1/en active Pending
- 2023-04-27 JP JP2023073187A patent/JP7646727B2/ja active Active
-
2025
- 2025-03-05 JP JP2025034492A patent/JP7852107B2/ja active Active
- 2025-03-05 JP JP2025034493A patent/JP7852108B2/ja active Active
- 2025-08-22 AU AU2025220842A patent/AU2025220842A1/en active Pending
- 2025-08-22 AU AU2025220841A patent/AU2025220841A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276383B1 (en) | Treatment of ophthalmological diseases | |
| IL289405A (en) | Personalized treatment of eye diseases | |
| LT3548061T (lt) | Neurologinių ligų gydymas | |
| IL282643A (en) | Soft combinations for the treatment of hematological diseases | |
| IL268357A (en) | Photoreceptor cells for the treatment of retinal diseases | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| IL269083A (en) | Methods for preventing and treating heart disease | |
| SG11202006374VA (en) | Treatment of demyelinating diseases | |
| SG11202007082PA (en) | Composition used for therapeutic treatment of skin disease | |
| IL282361A (en) | Treatment for neurological diseases | |
| PT3603621T (pt) | Lipossomas para o tratamento de doenças oculares | |
| SG11202001595SA (en) | Angio-3 for treatment of retinal angiogenic diseases | |
| SG11202010585WA (en) | New treatment of interstitial lung diseases | |
| ZA202002075B (en) | Compounds, compositions and methods for treatment of eye disorders and skin diseases | |
| IL269698B (en) | Methods for preventing or treating eye diseases | |
| PT3761982T (pt) | Utilização da nalfurafina no tratamento de doenças desmielinizantes | |
| GB202015959D0 (en) | Treatment of diseases involving NAD | |
| SG11202010034WA (en) | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY | |
| PT3377061T (pt) | Mirabegron para o tratamento de doenças da retina | |
| IL282898A (en) | Ophthalmic compounds and methods for treating skin and eye diseases | |
| GB201914516D0 (en) | Treatment of eye disease | |
| IL263837A (en) | Treatment of ocular disease | |
| GB201909438D0 (en) | Treatment of diseases | |
| GB201805556D0 (en) | Treatment of ophthalmological conditions | |
| GB201904764D0 (en) | Treatment of ophthalmological conditions |